GlassScriptPhysician profile
Deborah Tabulov
NPI 1497786131
$2,187.72
in general payments reported to CMS, 2019-2025
18 companies · $834 in 2025
The $834 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $138 · 2023: $304 · 2024: $626 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $445.46 | 2021-2024 | Collagenase Santyl, Regranex, Grafix Pl |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2024-2025 | Farxiga, Airsupra |
| Next Science LLC | $248.90 | 2023-2024 | Blastx, Xperience, Surgx |
| Organogenesis INC. | $140.20 | 2021 | |
| Gilead Sciences, INC. | $128.33 | 2025 | |
| Kyowa Kirin, INC. | $125.71 | 2025 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Amgen INC. | $125.00 | 2025 | Krystexxa |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2025 | Uptravi, Opsumit |
| Mimedx Group, INC. | $93.94 | 2025 | |
| Alexion Pharmaceuticals, INC. | $90.00 | 2025 | Strensiq |
| Kerecis Limited | $45.84 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Hartmann USA, INC. | $35.70 | 2021-2023 | Zetuvit Plus |
| Bioventus LLC | $33.02 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $17.75 | 2023 | V.A.C. Dermatac, Activ.A.C., 3m Coban |
| Lifenet Health | $16.48 | 2023 | |
| Molnlycke Health Care US, LLC | $16.39 | 2023 | Mextra Superabsorbant, Mepilex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Tabulov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.